Abstract Number: 1484 • ACR Convergence 2024
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP1-RA) are an emerging class of medications that significantly improve cardiometabolic outcomes. Whether these drugs may be useful in mitigating…Abstract Number: 1891 • ACR Convergence 2024
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…Abstract Number: 2114 • ACR Convergence 2024
CT and DXA Bone Fragility Evaluation After Bariatric Surgery
Background/Purpose: Bariatric surgery could impact bone metabolism and induce significant changes, leading to increased bone resorption and an increased risk of fractures.The primary objective was…Abstract Number: 2237 • ACR Convergence 2024
The Association Between Bariatric Surgery and Incident Rheumatoid Arthritis
Background/Purpose: Obesity is considered a controversial risk factor for developing rheumatoid arthritis (RA), and the association between weight change and RA incidence is inconclusive. The…Abstract Number: 2259 • ACR Convergence 2024
Effects of Anti-Obesity Medications in RA Patients
Background/Purpose: It is standard practice to advocate for weight loss in patients with rheumatoid arthritis (RA) and obesity. Obesity and rheumatoid arthritis are both independently…Abstract Number: 2350 • ACR Convergence 2024
Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
Background/Purpose: Smoking and obesity are common in patients with psoriatic arthritis (PsA) and can lead to higher disease activity and poorer response to treatment with…Abstract Number: 2386 • ACR Convergence 2024
Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by autoantibodies and disruption of multiple organs due to immunomodulatory dysfunction. Obesity is a…Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…Abstract Number: 0457 • ACR Convergence 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…Abstract Number: 0864 • ACR Convergence 2024
Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people…Abstract Number: 1050 • ACR Convergence 2024
The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity
Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…Abstract Number: 1187 • ACR Convergence 2024
Association of Depressive Symptoms and Multiple Joint Osteoarthritis with Pain Outcomes in the WE-CAN Trial
Background/Purpose: The Weight-loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN) trial was a community-based, pragmatic randomized clinical trial in men and women…Abstract Number: 1192 • ACR Convergence 2024
Relationship Between Measures of Fat Mass and Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis (MOST) Study
Background/Purpose: Obesity [defined by body mass index (BMI) ≥30 kg/m2] is an established risk factor for incident radiographic knee OA (ROA). However, the relative contributions…
- 1
- 2
- 3
- …
- 10
- Next Page »